Skip to main content


Technology Guidance - Drug

Sumatriptan for the treatment of acute migraine attacks Published on 3 May 2017

Guidance Recommendations
Following an evaluation of sumatriptan for the treatment of acute migraine attacks, sumatriptan 50mg tablet is recommended for listing on the MOH Standard Drug List 2 (SDL2) by the MOH Drug Advisory Committee in view of its clinically superior outcomes when used in combination with naproxen compared with either sumatriptan or naproxen monotherapy, and the low cost of subsidy.

This recommendation means that subsidies will apply to sumatriptan for the indications registered in Singapore:
  • Acute relief of migraine attacks with or without aura, including the acute treatment of migraine attacks associated with the menstrual period in women.

Get Acrobat Readeropens in a new window
Back to Top